AbbVie announced on 17th October that the US Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). The treatment is approved in 35 countries. The approval was supported by…
Category: Parkinson’s Disease
Ophthalmic acid – its role in motor function control
Brain molecule reverses movement deficits of Parkinson’s, offering new therapeutic target October 4th 2024: A research team from the University of California, Irvine is the first to reveal that a molecule in the brain – ophthalmic acid – unexpectedly acts like a neurotransmitter similar to dopamine in regulating motor function, offering a new therapeutic target…
Cannabis-based medicine for neurodegenerative diseases
Avextra announces the approval of NEUROBIS by the Italian Medicines Agency: A Phase II clinical trial Avextra AG, a European manufacturer and developer of Cannabis-based medicines located in Germany, has announced that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to…
US launch of CREXONT® for Parkinson’s disease
23 September 2024: Amneal Pharmaceuticals has announced that it has launched CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. “We are pleased to launch CREXONT and make it broadly available to healthcare providers and patients. The…
Phase 1 study of UB-312 shows promise in Parkinson’s disease
In a study published in Nature Medicine on 18th September 2024, Parkinson’s patients reported improved daily movement with Vaxxinity’s Parkinson’s drug UB-312. The small trial, which included work from researchers at the University of Texas, the Mayo Clinic, and the Michael J. Fox Foundation for Parkinson’s Research, included only 20 people with Parkinson’s. However, it…
CREXONT for Parkinson’s disease – Amneal’s capsules gain FDA approval
August 8th 2024: The US Food and Drug Administration (FDA) has granted approval to Amneal Pharmaceuticals‘ CREXONT (carbidopa/levodopa) extended-release capsules for the treatment of Parkinson’s disease. This novel oral formulation combines immediate-release granules and extended-release pellets, meaning that therapeutic levels of levodopa and carbidopa may be maintained with less frequent dosing to maximise “good on” time,…
CE Mark for Image Guided Programming Software for Deep Brain Stimulation
Boston’s Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions Boston Scientific Corporation has obtained a CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology, which when used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) Systems, can provide…
How can scientists model the human brain?
bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…
Gait freezing: soft robotic, wearable device improves walking for individual with Parkinson’s disease
Robotic exosuit eliminated gait freezing 5 January, 2024; Gait freezing is one of the most common and debilitating symptoms of Parkinson’s disease, with people suddenly losing the ability to move their feet, often mid-stride, resulting in a series of staccato stutter steps that get shorter until they stop altogether. These episodes are one of the…
